Tocagen Achieves Key Development Milestone for Lead Product: Phase 2 Randomized Trial in Patients with Recurrent Brain Cancer Fully Enrolled

SAN DIEGO, Feb. 23, 2017 /PRNewswire/ -- Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced it has completed patient enrollment in the Phase 2 portion of Toca 5, a…
Continue Reading »